Paul Tudor Jones’s Carisma Therapeutics CARM Stock Holding History

Paul Tudor Jones’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-806	Closed	-$75K	–	2475
2021 Q2	$75K	Buy	+806	New	+$51.4K	﹤0.01%	1541

Other funds holding CARM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Paul Tudor Jones's CARM Position: Q3 2021 in Review

Paul Tudor Jones sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 806 shares — an estimated $75K sold.

Paul Tudor Jones first reported a position in CARM in Q2 2021 and held it in 1 quarter. The position peaked at $75K in Q2 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

Paul Tudor Jones reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
Paul Tudor Jones sold 806 Carisma Therapeutics shares in Q3 2021, an estimated $75K.
Paul Tudor Jones first reported a position in Carisma Therapeutics in Q2 2021 and held it in 1 quarter.
Paul Tudor Jones's Carisma Therapeutics position peaked at $75K in Q2 2021.
103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.